skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response

Abstract

Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can be safely targeted with Auger emitters to induce DNA damage in tumors. Here, we investigated a radioiodinated PARP inhibitor, [125I]KX1, and show drug target specific DNA damage and subsequent killing of BRCA1 and non-BRCA mutant ovarian cancer cells at sub-pharmacological concentrations several orders of magnitude lower than traditional PARP inhibitors. Furthermore, we demonstrated that viable tumor tissue from ovarian cancer patients can be used to screen tumor radiosensitivity ex-vivo, enabling the direct assessment of therapeutic efficacy. Finally, we showed tumors can be imaged by single-photon computed tomography (SPECT) with PARP theranostic, [123I]KX1, in a human ovarian cancer xenograft mouse model. These data support the utility of PARP-1 targeted radiopharmaceutical therapy as a theranostic option for PARP-1 overexpressing ovarian cancers.


Citation Formats

Riad, Aladdin, Gitto, Sarah B., Lee, Hwan, Winters, Harrison D., Martorano, Paul M., Hsieh, Chia-Ju, Xu, Kuiying, Omran, Dalia K., Powell, Jr., Daniel J., Mach, Robert H., and Makvandi, Mehran. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. Switzerland: N. p., 2020. Web. https://doi.org/10.3390/molecules25246029.
Riad, Aladdin, Gitto, Sarah B., Lee, Hwan, Winters, Harrison D., Martorano, Paul M., Hsieh, Chia-Ju, Xu, Kuiying, Omran, Dalia K., Powell, Jr., Daniel J., Mach, Robert H., & Makvandi, Mehran. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response. Switzerland. https://doi.org/10.3390/molecules25246029
Riad, Aladdin, Gitto, Sarah B., Lee, Hwan, Winters, Harrison D., Martorano, Paul M., Hsieh, Chia-Ju, Xu, Kuiying, Omran, Dalia K., Powell, Jr., Daniel J., Mach, Robert H., and Makvandi, Mehran. Sat . "PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response". Switzerland. https://doi.org/10.3390/molecules25246029.
@article{osti_1737695,
title = {PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response},
author = {Riad, Aladdin and Gitto, Sarah B. and Lee, Hwan and Winters, Harrison D. and Martorano, Paul M. and Hsieh, Chia-Ju and Xu, Kuiying and Omran, Dalia K. and Powell, Jr., Daniel J. and Mach, Robert H. and Makvandi, Mehran},
abstractNote = {Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can be safely targeted with Auger emitters to induce DNA damage in tumors. Here, we investigated a radioiodinated PARP inhibitor, [125I]KX1, and show drug target specific DNA damage and subsequent killing of BRCA1 and non-BRCA mutant ovarian cancer cells at sub-pharmacological concentrations several orders of magnitude lower than traditional PARP inhibitors. Furthermore, we demonstrated that viable tumor tissue from ovarian cancer patients can be used to screen tumor radiosensitivity ex-vivo, enabling the direct assessment of therapeutic efficacy. Finally, we showed tumors can be imaged by single-photon computed tomography (SPECT) with PARP theranostic, [123I]KX1, in a human ovarian cancer xenograft mouse model. These data support the utility of PARP-1 targeted radiopharmaceutical therapy as a theranostic option for PARP-1 overexpressing ovarian cancers.},
doi = {10.3390/molecules25246029},
journal = {Molecules},
number = 24,
volume = 25,
place = {Switzerland},
year = {2020},
month = {12}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.3390/molecules25246029

Save / Share:

Works referenced in this record:

The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
journal, July 2010


Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
journal, July 2015


Auger radiation targeted into DNA: a therapy perspective
journal, August 2006

  • Buchegger, Franz; Perillo-Adamer, Florence; Dupertuis, Yves M.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 33, Issue 11
  • DOI: 10.1007/s00259-006-0187-2

Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib
journal, March 2018

  • Kossatz, Susanne; Carney, Brandon; Farley, Christopher
  • Journal of Nuclear Medicine, Vol. 59, Issue 8
  • DOI: 10.2967/jnumed.117.205765

Radioimmunotherapy with alpha-emitting nuclides
journal, September 1998

  • McDevitt, Michael R.; Sgouros, George; Finn, Ronald D.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 25, Issue 9
  • DOI: 10.1007/s002590050306

Lethality of Auger Electrons from the Decay of Bromine-77 in the DNA of Mammalian Cells
journal, May 1982

  • Kassis, A. I.; Adelstein, S. J.; Haydock, C.
  • Radiation Research, Vol. 90, Issue 2
  • DOI: 10.2307/3575714

Indirect Mechanisms Contribute to Biological Effects Produced by Decay of DNA-Incorporated Iodine- 125 in Mammalian Cells In Vitro: Clonogenic Survival
journal, February 1998

  • Walicka, Malgorzata A.; Adelstein, S. James; Kassis, Amin I.
  • Radiation Research, Vol. 149, Issue 2
  • DOI: 10.2307/3579923

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
journal, April 2018

  • Makvandi, Mehran; Pantel, Austin; Schwartz, Lauren
  • Journal of Clinical Investigation, Vol. 128, Issue 5
  • DOI: 10.1172/JCI97992

Targeted Brain Tumor Radiotherapy Using an Auger Emitter
journal, February 2020


Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types
journal, August 2010


Rapid Cu-Catalyzed [ 211 At]Astatination and [ 125 I]Iodination of Boronic Esters at Room Temperature
journal, March 2018


PARP inhibitors: Synthetic lethality in the clinic
journal, March 2017


Therapeutic Radionuclides: Biophysical and Radiobiologic Principles
journal, September 2008


MIRD Pamphlet No. 25: MIRDcell V2.0 Software Tool for Dosimetric Analysis of Biologic Response of Multicellular Populations
journal, July 2014


PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma
journal, March 2018

  • Jannetti, Stephen A.; Carlucci, Giuseppe; Carney, Brandon
  • Journal of Nuclear Medicine, Vol. 59, Issue 8
  • DOI: 10.2967/jnumed.117.205054

Improved production of 76Br, 77Br and 80mBr via CoSe cyclotron targets and vertical dry distillation
journal, January 2020